. Author manuscript; available in PMC: 2017 Sep 6.

Published in final edited form as: Diab Vasc Dis Res. 2015 Jul 20;12(6):411–419. doi: 10.1177/1479164115592638

Table 5.

Association between log adiponectin and 1-year composite outcomes of all-cause mortality or hospitalization for heart failure (N = 120).^a

	All-cause mortality (no. of outcomes = 10)		Hospitalization for heart failure (no. of outcomes = 9)		Composite of all-cause hospitalization mortality and for heart failure (no. of outcomes = 14)

Unadjusted models	HR	p	HR	p	HR	p
Age	1.11	<0.001	1.08	0.011	1.09	<0.001
Sex, men	0.28	0.046	0.19	0.021	0.30	0.025
BMI	0.81	0.043	0.76	0.016	0.82	0.021
DM	1.44	0.60	1.64	0.48	1.32	0.64
History of MI	5.68	0.012	2.94	0.10	3.12	0.035
History of HF	9.74	<0.001	18.0	<0.001	10.3	<0.001
Log hs-CRP (mg/L)	3.25	0.024	3.91	0.034	3.20	0.014
BNP (pg/mL)	1.00	0.16	1.00	0.29	1.00	0.13
GIK treatment	0.29	0.12	0.14	0.07	0.31	0.07
Log adiponectin, per 1 μg/mL	0.54	0.20	0.43	0.10	0.51	0.09
Adiponectin quartiles
Quartile 1	Ref	Ref	Ref	Ref	Ref	Ref
Quartile 2	0.20	0.14	0.50	0.42	0.50	0.33
Quartile 3	0.69	0.61	0.58	0.50	0.74	0.64
Quartile 4	0.20	0.15	0.25	0.21	0.17	0.10

BMI: body mass index; BNP: brain-type natriuretic peptide; GIK: glucose–insulin–potassium; Hgb A1C: glycosylated haemoglobin; HF: heart failure; HR: hazard ratio; hs-CRP: high-sensitivity C-reactive protein; MI: myocardial infarction.

First available adiponectin measurement for each participant was used in this analysis.